Referral of ZONEGRAN (Zonisamide), WELLBUTRIN and ZYBAN (Bupropion), and RENAGEL (Sevelamer) for the Conduct of Pediatric Studies

الملخص

The Food and Drug Administration (FDA) is announcing the referral of ZONEGRAN (zonisamide), WELLBUTRIN and ZYBAN (bupropion), and RENAGEL (sevelamer) to the Foundation for the National Institutes of Health (the Foundation) for the conduct of pediatric studies. FDA referred these drugs to the Foundation on November 14, 2003, and is publishing this notice of the referrals.